Tumor cell-derived spermidine is an oncometabolite that suppresses TCR clustering for intratumoral CD8

Area of Science:

• Immunology
• Metabolic pathways
• Cancer research

Background:

• T cell activation is crucial for antitumor immunity.
• Tumors employ mechanisms like PD-L1/PD-1 to evade immune destruction.
• Alternative tumor evasion strategies require further investigation.

Purpose of the Study:

• To identify novel mechanisms of tumor immune evasion.
• To investigate the role of oncometabolites in T cell suppression.
• To explore spermidine as a potential therapeutic target in cancer immunotherapy.

Main Methods:

• Secretome profiling of necrotic tumor cells.
• Analysis of T cell receptor (TCR) signaling pathways.
• Syngeneic mouse models to evaluate antitumor responses.
• Combination therapy with polyamine synthesis inhibitors and anti-PD-1 antibodies.

Main Results:

• Spermidine identified as an oncometabolite inhibiting TCR signaling.
• Spermidine downregulates plasma membrane cholesterol, suppressing TCR clustering.
• Spermidine is abundant in the tumor immune microenvironment (TIME).
• Polyamine synthesis inhibition enhances CD8+ T cell-mediated antitumor immunity.
• Combination therapy with polyamine synthesis inhibitor and anti-PD-1 yields synergistic antitumor effects.

Conclusions:

• Spermidine acts as a metabolic T cell checkpoint, contributing to tumor immune evasion.
• Targeting spermidine synthesis represents a novel strategy to enhance cancer immunotherapy.
• Combined inhibition of spermidine synthesis and PD-1 pathway offers a potent approach for antitumor immunity.